Active placebo

Active placebo names a way of thinking about psychedelics that holds two possibilities together: the drugs do something, yet much of what happens may be generated by the person undergoing the experience. The idea captures a central tension in Sidney Cohen’s account of psychedelic therapy: suggestibility can make therapeutic insight scientifically difficult to verify without necessarily making it therapeutically useless.

The analogy and its source

Cohen observed that patients’ reported insights could reflect the therapist’s framework. Under LSD, patients working with Freudian therapists might return with explanations framed around childhood trauma, sexual drives, and oedipal emotions; those working with Jungian therapists might report archetypes, while Rankian patients might recover memories of birth trauma. As Cohen put it, “under LSD the fondest theories of the therapist are confirmed by his patient.” The experience could therefore amplify expectations and interpretive frameworks rather than independently establish the truth of what patients reported.

The term “active placebo” offers a way to describe this uncertainty without reducing the experience to nothing. Psychedelics may have real effects, while the particular meanings and explanations that emerge may be substantially self-generated. Andrew Weil proposed the term in his 1972 book, The Natural Mind. Stanislav Grof expressed a related idea by calling psychedelics “nonspecific amplifiers” of mental processes: they intensify or bring forward processes without, in this account, dictating one specific psychological content.

Therapeutic usefulness and scientific doubt

Cohen’s question was whether radical suggestibility necessarily invalidated therapy as well as scientific claims. He allowed that “any explanation of the patient’s problems, if firmly believed by both the therapist and the patient, constitutes insight or is useful as insight.” On this view, a therapeutic interpretation might help even if the experience could not demonstrate that the interpretation was objectively correct. The potential benefit and the evidentiary weakness could coexist.

Cohen also called this position “nihilistic”: if the patient’s conviction and the therapist’s framework can make an explanation useful, scientific standards for distinguishing discovery from expectation become difficult to maintain. The analogy to placebo treatment sharpens the problem. A treatment may produce an effect without validating the explanation given for it, leaving scientists uncertain about what, precisely, has acted and how much of the result comes from the patient’s own processes.

The limits of the model

Active placebo is therefore a framing concept, not a claim that psychedelic experiences are simply inert or that their reported insights are necessarily false. It marks the gap between an experience’s felt or therapeutic significance and what that experience can establish scientifically. Cohen’s ambivalence reflects that distinction: he continued to believe in LSD’s therapeutic power, particularly for anxiety in cancer patients, while warning about its dangers and challenging colleagues when their claims strayed from scientific rigor. The concept preserves both sides of his judgment—the possibility of healing and the difficulty of knowing what the drug, the patient, and the therapist each contribute.